What Is OxyContin Made Of? Ingredients Explained

OxyContin is a brand-name extended-release tablet whose active ingredient is oxycodone hydrochloride, a semi-synthetic opioid derived from thebaine, a compound found naturally in the opium poppy. But the active drug itself is only part of the story. The tablet’s inactive ingredients, particularly the polymers and coatings engineered to control how the drug releases and to discourage tampering, are central to understanding what OxyContin actually is and why its formulation has been a source of both medical progress and public controversy.

The Active Ingredient and Where It Comes From

Oxycodone hydrochloride is classified as a semi-synthetic opioid. That means it starts in nature but finishes in a lab. The raw material is thebaine, one of the alkaloids produced by the opium poppy (Papaver somniferum). Opium poppy is the same plant that yields morphine and codeine, but thebaine is a different alkaloid with relatively little painkilling effect on its own. Certain poppy cultivars have been bred to produce elevated thebaine content specifically for pharmaceutical use.¹ Chemists then modify thebaine’s molecular structure through a series of chemical reactions to produce oxycodone. The “hydrochloride” part refers to the salt form used in the tablet, which helps the drug dissolve properly and remain stable.

Interestingly, researchers have also demonstrated that opioid precursors like thebaine can be biosynthesized in engineered yeast starting from simple sugar, a proof of concept that could eventually change how opioid raw materials are sourced.² For now, though, commercial oxycodone still traces back to poppy-derived thebaine.

OxyContin tablets come in several strengths, ranging from 10 mg to 80 mg of oxycodone hydrochloride per tablet. The “extended-release” label means each tablet is engineered to deliver oxycodone gradually over roughly 12 hours, rather than dumping the entire dose into the bloodstream at once. That slow release is the core design principle behind the tablet, and it depends entirely on the inactive ingredients that surround the drug.

How Oxycodone Works in the Body

Once oxycodone enters the bloodstream, it binds to mu-opioid receptors in the brain and spinal cord. These are the same receptors that morphine targets, and they are responsible for both pain relief and the euphoric effects that make opioids prone to misuse. Research comparing oxycodone and morphine in brain regions involved in pain processing has shown that both drugs activate these receptors, though the pattern and degree of activation can differ depending on the pain condition being studied.³

For patients taking OxyContin as prescribed, the extended-release design keeps plasma oxycodone concentrations relatively steady over the dosing interval. When swallowed intact, the tablet reaches peak blood levels at around five hours after dosing.⁴ That gradual curve is what distinguishes OxyContin from immediate-release oxycodone products, which hit their peak much faster and require dosing every four to six hours.

The Inactive Ingredients and Why They Matter

The active drug accounts for a tiny fraction of each tablet’s total weight. The rest is made up of inactive ingredients, sometimes called excipients, that serve specific pharmaceutical functions. These are not just filler. Each one plays a role in controlling how the tablet behaves physically, how the drug releases over time, and how resistant the tablet is to tampering.

The most important inactive ingredient in the current OxyContin formulation is high-molecular-weight polyethylene oxide, commonly abbreviated as PEO. PEO is a water-soluble polymer that does double duty. First, it acts as the matrix that holds the drug and controls its release rate. As the tablet slowly absorbs water in the gastrointestinal tract, the PEO swells and forms a gel, allowing oxycodone to diffuse out gradually rather than all at once. Second, PEO is the backbone of OxyContin’s abuse-deterrent properties, providing the mechanical toughness that makes the tablet resist crushing and the viscosity that makes dissolved tablets resist injection through a needle.⁵

Other inactive ingredients include butylated hydroxytoluene (BHT), an antioxidant commonly used in food and pharmaceuticals to prevent degradation; magnesium stearate, a lubricant that helps the tablet release cleanly from manufacturing molds and aids swallowing; and various colorants and coatings that distinguish different dosage strengths.⁶ None of these are exotic chemicals. BHT shows up on the ingredient lists of breakfast cereals and cosmetics. Magnesium stearate is one of the most widely used pharmaceutical excipients in the world. PEO itself is used in laxatives, wound dressings, and even toothpaste. But in OxyContin, they are combined at specific ratios and processed under specific conditions to achieve something no single ingredient could do alone.

The Reformulation and RESISTEC Technology

The OxyContin tablets on the market today are not the same product that was originally approved. The original formulation, introduced in 1996, used a different extended-release matrix that could be relatively easily defeated. A person could crush the tablet into powder and snort it, or dissolve it in water and inject it, bypassing the extended-release mechanism and delivering the full dose at once. That vulnerability contributed to widespread misuse.

In 2010, the manufacturer introduced a reformulated tablet built around what it calls RESISTEC technology. The key change was incorporating high-molecular-weight PEO and subjecting the tablets to a thermal manufacturing process. Heating PEO causes it to fuse and develop thermoplastic properties that dramatically increase the tablet’s mechanical strength.⁷ The result is a tablet that resists being crushed into fine powder. And if someone does manage to break it apart and dissolve the fragments in water, the PEO swells into a thick, gummy gel that cannot easily be drawn through a syringe.

A study testing the reformulated tablet among people who reported abusing prescription opioids found striking differences. When the original OxyContin tablet was crushed, nearly all the resulting particles were fine enough to snort. With the reformulated tablet, the crushed particles were far larger and clumpier. Nearly all participants said they would be willing to snort the powder from the original formulation, while only a small fraction said they would snort the tampered result from the reformulated version.⁸ The reformulation does not make abuse impossible, but it raises the barrier considerably for the most dangerous routes of administration.

Pharmacokinetic studies show the practical effect of that barrier. When the reformulated OxyContin tablet is crushed and swallowed, the crushed version behaves similarly to crushed immediate-release oxycodone, rapidly delivering the drug into the bloodstream.⁹ That means the abuse-deterrent design is more effective against snorting and injection than against chewing or crushing and swallowing. This is an important limitation, and it is one of the reasons other formulations have been developed using different approaches.

How OxyContin Compares to Other Abuse-Deterrent Opioids

OxyContin’s PEO-based RESISTEC approach is one of several abuse-deterrent strategies now on the market. Another extended-release oxycodone product, Xtampza ER, uses a technology called DETERx, which works differently. Rather than relying on a hard-to-crush matrix, DETERx encapsulates oxycodone in microspheres designed to maintain their extended-release behavior even when chewed or crushed. That product is the only extended-release opioid without a boxed warning against crushing or chewing.¹⁰

The pharmacokinetic profiles illustrate the difference. When OxyContin is crushed and taken orally, it loses its extended-release characteristics and behaves like an immediate-release product. When Xtampza ER is crushed and taken orally, it retains a slower, more gradual release with a lower and delayed peak blood level.⁴ For OxyContin, the abuse-deterrent properties are primarily physical: the tablet is hard to turn into a form suitable for snorting or injecting. For Xtampza, the deterrence operates more at a pharmacokinetic level: even after manipulation, the drug still releases slowly.

These differences highlight that the inactive ingredients are not just packaging. They fundamentally determine the clinical profile and safety properties of the product. Two tablets can contain the same drug in the same dose and behave very differently in the body depending on what else is in the tablet and how it was manufactured.

What Happens When People Inject the Reformulated Tablets

One of the more alarming findings related to OxyContin’s reformulation concerns what happens when people attempt to dissolve and inject the new tablets despite the deterrent features. The PEO that makes the tablet gummy in solution does not simply make injection difficult. When injected intravenously, high-molecular-weight PEO appears to cause a serious blood disorder called thrombotic microangiopathy, or TMA. This condition involves damage to small blood vessels, leading to destruction of red blood cells and dangerous drops in platelet counts.

Case reports have documented TMA in patients who injected reformulated OxyContin, and researchers have noted that the same pattern shows up with other opioid products containing PEO coatings, suggesting the polymer itself is the culprit rather than the oxycodone.¹¹ Animal studies have reinforced this connection: rats injected intravenously with high-molecular-weight PEO developed similar blood abnormalities in a dose-dependent fashion.⁶

This is a grim irony of the reformulation. The inactive ingredient designed to deter injection does deter many people from attempting it, but for those who inject anyway, the PEO introduces a new and potentially life-threatening harm that did not exist with the original formulation. Clinicians treating people who inject opioids need to be aware that unexplained blood cell abnormalities in a patient may be related to injected PEO rather than to the opioid itself.

Alcohol and the Risk of Dose Dumping

An ongoing concern with any extended-release medication is what happens if the release mechanism breaks down in the presence of alcohol. The worry is called “dose dumping,” where the entire drug payload releases at once rather than gradually, potentially causing an overdose. This is particularly dangerous with opioids, where higher-than-intended blood levels can suppress breathing.

For OxyContin’s formulation, studies have tested what happens when the tablet is exposed to alcohol. In healthy volunteers, taking a once-daily oxycodone extended-release formulation with 20% alcohol produced no meaningful change in how the drug was absorbed. With 40% alcohol (roughly equivalent to spirits), there was a slight increase in total drug absorption but no increase in the peak absorption rate, and the extended-release profile was maintained.¹² Earlier laboratory testing of prolonged-release opioid formulations similarly found that their release mechanisms held up under ethanol exposure conditions, with no evidence of dose dumping.¹³

That said, the interaction between opioids and alcohol is dangerous for reasons beyond dose dumping. Both substances depress the central nervous system, and their combined sedative effects can be lethal even when neither substance alone would cause harm at the given dose. The absence of dose dumping does not make it safe to drink while taking OxyContin; it means one specific mechanism of danger is less likely to occur with the current formulation.

The Manufacturing Process Behind the Tablet’s Toughness

The physical properties of OxyContin’s reformulated tablets do not come solely from choosing PEO as an ingredient. The manufacturing process matters just as much. The tablets undergo a thermal treatment, essentially a controlled heating step, that changes how the PEO molecules behave. When heated to the right temperature range, PEO’s thermoplastic nature causes the polymer chains to flow and fuse together, dramatically increasing the mechanical strength of the resulting tablet.⁷

Researchers studying this process have found that the temperature window matters. Too little heat, and the PEO does not fuse enough to resist crushing. Too much heat, and the mechanical strength actually decreases, with the tablet becoming easier to break apart. One study found that tablets treated at excessively high temperatures could be crushed in a ball mill with most particles ending up below the size that would concern abuse-deterrent designers.⁷ In other words, the abuse-deterrent properties are not just about what is in the tablet but about how precisely it was made. Academic groups attempting to mimic OxyContin’s composition for research purposes have had to carefully replicate both the ingredient ratios and the thermal processing to achieve comparable results.⁷

From Poppy to Polymer

It is worth stepping back to appreciate just how many layers of engineering sit between the opium poppy and the tablet a patient swallows. Poppy plants are cultivated in regulated agricultural settings, with specific cultivars selected for high thebaine content rather than high morphine content.¹ Thebaine is extracted, chemically converted to oxycodone, and then formulated into the hydrochloride salt. That active ingredient is blended with PEO and other excipients, extruded or compressed into tablet form, thermally processed to fuse the matrix, coated for identification and swallowing ease, and packaged. Each step is governed by pharmaceutical manufacturing standards that dictate acceptable ranges for particle size, hardness, dissolution rate, and dozens of other parameters.

The finished product is something that would be unrecognizable to anyone looking at the raw poppy. Fewer than 80 milligrams of oxycodone in even the highest-strength tablet, embedded in a polymer matrix engineered at the molecular level to control release timing, resist physical manipulation, and gel in the presence of water. The inactive ingredients outweigh the active drug many times over. In a real sense, OxyContin is less a drug with some packaging and more a delivery system that happens to contain a drug. Whether that delivery system succeeds in its dual goals of pain relief and abuse deterrence depends not just on its ingredients but on how those ingredients interact, how they were processed, and whether the patient takes the tablet as designed.